Sorafenib Tosylate Tablet is used for treatment of primary kidney cancer and is known to work by inhibiting platelet derived growth factor, VEGF, & c-KIT. It blocks RAF kinase which is considered to have an important role in cell division & proliferation of tumor cells. This tablet blocks tumor angiogenesis by inhibiting PDGFR-beta signaling cascade. Sorafenib Tosylate Tablet has excellent protein binding ability of around 99.5% with elimination half life of 25 to 48 hours.
Metabolized by CYP3A4 & UGT 1A9
Excreted in feces
Ideal to be used for liver cancer